US life sciences damages averaged $33.5m between 2019-2025

Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Regulation & Industry

G 1/25: EPO settles controversial patent description question

4 September 2026 Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.

Regulation & Industry

California votes for law to restrict use of genAI by lawyers

4 September 2026 Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.

Regulation & Industry

FDA targets faster generic approvals in drive to slash drug prices

27 August 2026 Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.

More features

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

10x Genomics wins latest round in Parse patent dispute

Sun Pharma import ban back in force after Squires intervention

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Pinsents expands German patent practice with partner duo

US life sciences damages averaged $33.5m between 2019-2025

More on this story

Editor's picks

Editor's picks

More features